由瘤微环境诱导的化学疗法霍尔梅西斯在耐火性卵巢癌中
Xuboya Chang1,2, Satoshi Tamauchi3, Atsushi Nakagawa1
1Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan.
Scientific reports
|January 3, 2025
概括
低剂量的化疗可以意外地促进卵巢癌细胞的生长,特别是在低氧环境中. 这种由细胞周期变化和氧化应激驱动的霍梅西斯效应,挑战了标准治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 晚期卵巢癌往往会对化疗有不同的反应.
- 瘤微环境 (TME) 显著影响治疗疗效.
- 低剂量药物刺激癌症生长的化学疗法激进症是一个鲜为人知的现象.
研究的目的:
- 为了研究卵巢癌细胞中的化疗性荷尔梅斯.
- 探索瘤微环境 (TME),特别是缺氧,在这种现象中的作用.
- 阐明低剂量化疗诱导的增殖背后的分子机制.
主要方法:
- 对NOS3卵巢癌细胞 (包括耐药变体) 暴露于低剂量的西斯 (CDDP) 和帕克利塔塞尔 (PTX).
- 在正常和缺氧条件下的细胞增殖的评估.
- 细胞循环进展 (G2/M检查点,线性),活性氧物种 (ROS) 途径和谷氨水平的分析.
主要成果:
- 低剂量的CDDP和PTX增强了NOS3卵巢癌细胞的增殖,特别是耐药变体.
- 缺氧条件放大了霍尔梅西斯效应.
- 低剂量的CDDP调高了细胞循环进展途径 (G2/M,线性),并增加了ROS和谷氨水平,促进了细胞存活.
结论:
- 化疗激素是卵巢癌治疗的重要因素,受TME的影响.
- 标准的高剂量化疗策略可能由于hormesis.
- 向化机制对于开发耐火性卵巢癌的有效治疗方法至关重要.
相关概念视频
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


